Discovery and structure optimization of a series of isatin derivatives as Mycobacterium tuberculosis chorismate mutase inhibitors

Chemical Biology and Drug Design

Volumn 83, Issue 4, 2014, Pages 498-506

  Jeankumar, Variam U ^a   Alokam, Reshma ^a   Sridevi, Jonnalagadda P ^a   Suryadevara, Priyanka ^a   Matikonda, Siddharth S ^a   Peddi, Santosh ^a   Sahithi, Seedarala ^a   Alvala, Mallika ^a   Yogeeswari, Perumal ^a   Sriram, Dharmarajan ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

chorismate mutase; isatin; Mycobacterium tuberculosis; tuberculosis

Indexed keywords

3 ((5 NITROTHIOPHEN 2 YL)METHYLENE)INDOLIN 2 ONE; 3 (4 NITROBENZYLIDENE)INDOLIN 2 ONE; ISATIN; ISATIN DERIVATIVE; N ACETYL DERIVATIVE; N BENZENE DERIVATIVE; OXIME DERIVATIVE; SEMICARBAZONE; THIOSEMICARBAZONE; UNCLASSIFIED DRUG; CHORISMATE MUTASE; ENZYME INHIBITOR;

ANIMAL CELL; ARTICLE; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG DEVELOPMENT; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TUBERCULOSIS; WHOLE CELL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; X RAY CRYSTALLOGRAPHY;

CHORISMATE MUTASE; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; ENZYME ACTIVATION; ENZYME INHIBITORS; ISATIN; MOLECULAR STRUCTURE; MYCOBACTERIUM TUBERCULOSIS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84899019383     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12265     Document Type: Article

References (36)

1. Duncan K., (2004) Identification and validation of novel drug targets in tuberculosis. Curr Pharm Des; 10: 3185-3194. (Pubitemid 39276608)
2. Okvist M., Dey R., Sasso S., Grahn E., Kast P., Krengel U., (2006) 1.6 A crystal structure of the secreted chorismate mutase from Mycobacterium tuberculosis: novel fold topology revealed. J Mol Biol; 357: 1483-1499.
3. Roderer K., Kast P., (2009) Evolutionary cycles for pericyclic reactions-or why we keep mutating mutases. Chimia; 63: 313-317.
4. Sasso S., Ramakrishnan C., Gamper M., Hilvert D., Kast P., (2005) Characterization of the secreted chorismate mutase from the pathogen Mycobacterium tuberculosis. FEBS J; 272: 375-389.
5. Kim S.K., Reddy S.K., Nelson B.C., Vasquez G.B., Davis A., Howard A.J., Patterson S., Gilliland G.L., Ladner J.E., Reddy P.T., (2006) Biochemical and structural characterization of the secreted chorismate mutase (Rv1885c) from Mycobacterium tuberculosis H37Rv: an AroQ enzyme not regulated by the aromatic amino acids. J Bacteriol; 24: 8638-8648. (Pubitemid 44894065)
6. Sasso S., Okvist M., Roderer K., Gamper M., Codoni G., Krengel U., Kast P., (2009) Structure and function of a complex between chorismate mutase and DAHP synthase: efficiency boost for the junior partner. EMBO J; 28: 2128-2142.
7. Djamei A., Schipper K., Rabe F., Ghosh A., Vincon V., Kahnt J., Osorio S., et al,. (2011) Metabolic priming by a secreted fungal effector. Nature; 478: 395.
8. Munack S., Leroux V., Roderer K., Okvist M., van Eerde A., Gundersen L.L., Krengel U., Kast P., (2012) When inhibitors do not inhibit: critical evaluation of rational drug design targeting chorismate mutase from Mycobacterium tuberculosis. Chem Biodivers; 11: 2507-2527.
9. Agrawal H., Kumar A., Bal N.C., Siddiqi M.I., Arora A., (2007) Ligand based virtual screening and biological evaluation of inhibitors of chorismate mutase (Rv1885c) from Mycobacterium tuberculosis H37Rv. Bioorg Med Chem Lett; 17: 3053-3058. (Pubitemid 46702633)
10. Sikdar S.,. Ph.D. thesis, Aston University, UK, 2010.
11. Adepu R., Kumar K.S., Sandra S., Rambabu D., Rama Krishna G., Reddy C.M., Kandale A., Misra P., Pal M., (2012) C-N bond formation under Cu-catalysis: Synthesis and in vitro evaluation of N-aryl substituted thieno[2,3-d]pyrimidin- 4(3H)-ones against chorismate mutase. Bioorg Med Chem; 20: 5127-5138.
12. 3 induced (hetero)arylation of 2,3-dichloroquinoxaline: a one-pot synthesis of mono/disubstituted quinoxalines as potential antitubercular agents. Bioorg Med Chem; 20: 1711-1722.
13. Shiva Kumar K., Adepu R., Sandra S., Rambabu D., Rama Krishna G., Malla Reddy C., Misra P., Pal M., (2012) Cu-mediated N-arylation of 1,2,3-triazin-4-ones: synthesis of fused triazinone derivatives as potential inhibitors of chorismate mutase. Bioorg Med Chem Lett; 22: 1146-1150.
14. Ram Reddy T., Srinivasula Reddy L., Rajeshwar Reddy G., Nuthalapatia V.S., Lingappa Y., Sandra S., Kapavarapua R., Misra P., Pal M., (2011) A Pd-mediated new strategy to functionalized 2-aminochromenes: their in vitro evaluation as potential anti tuberculosis agents. Bioorg Med Chem Lett; 21: 6433-6439.
15. Bartlett P.A., Johnson C.R., (1985) An inhibitor of chorismate mutase resembling the transition-state conformation. J Am Chem Soc; 107: 7792-7793.
16. Sogo S.G., Widlanski T.S., Hoare J.H., Grimshaw C.E., Berchtold G.A., Knowles J.R., (1984) Stereochemistry of the rearrangement of chorismate to prephenate: chorismate mutase involves a chair transition state. J Am Chem Soc; 106: 2701-2703.
17. Garden S.J., Torres J.C., da Silva L.E., Pinto A.C., (1998) A convenient methodology for the N-Alkylation of isatin compounds. Syn Comm; 28: 1679-1689. (Pubitemid 28216203)
18. Silviya D.F., Suhaib S., Srinivasaraghava K., Wolfgang S., Manfred J., (2012) Rhodanine carboxylic acids as novel inhibitors of histone acetyltransferases. Med Chem Commun; 3: 305-311.
19. Chan D.M.T., Monaco K.L., Wang R.P., Winter M.P., (1998) New N- and O-arylations with phenylboronic acids and cupric acetate. Tetrahedron Lett; 39: 2933-2936. (Pubitemid 28184063)
20. Lam P.Y.S., Clark C.G., Saubern S., Adams J., Winters M.P., Chan D.M.T., Combs A., (1998) New aryl/Heteroaryl C-N bond cross-coupling reactions via arylboronic acid/cupric acetate arylation. Tetrahedron Lett; 39: 2941-2944. (Pubitemid 28184065)
21. Jacobs T.L., Winstein S., Linden G.B., Robson J.H., Levy F.E., Seymour D., (1955) 2-Hydroxycinchoninic acid. Org Synth; 3: 456.
22. Chiyanzu I., Hansell E., Gut J., Rosenthal P.J., McKerrow J.H., Chibale K., (2003) Synthesis and evaluation of isatins and thiosemicarbazone derivatives against cruzain, falcipain-2 and rhodesain. Bioorg Med Chem Lett; 13: 3527-3530. (Pubitemid 37141422)
23. Bal T.R., Balasubramani A., Yogeeswari P., Sriram D., (2005) Synthesis and evaluation of anti-HIV activity of isatin beta-thiosemicarbazone derivatives. Bioorg Med Chem Lett; 15: 4451-4455. (Pubitemid 41253873)
24. Frank W., Elsebet O.N., Jergen D., Jensen L.H., (1993) Isatin oximes-A novel series of bioavailable non-NMDA antagonists. Bioorg Med Chem Lett; 3: 105-106. (Pubitemid 23028334)
25. Verma M., Pandeya S.N., Singh K.N., Stables J.P., (2004) Anticonvulsant activity of Schiff bases of isatin derivatives. Acta Pharm; 54: 49.
26. Martinez F., Naarmann H., (1990) New isatin derivatives: synthesis and reactions. Synth Met; 39: 195-203.
27. Hartwig J.F., (1997) Palladium-catalyzed amination of aryl halides: mechanism and rational catalyst design. Synlett; 4: 329-340. (Pubitemid 127498130)
28. Huang X., Anderson K.W., Zim D., Jiang L., Klapars A., Buchwald S.L., (2003) Expanding Pd-catalyzed C-N bond-forming processes: the first amidation of aryl sulfonates, aqueous amination, and complementarity with Cu-catalyzed reactions. J Am Chem Soc; 125: 6653-6655. (Pubitemid 36667448)
29. Strieter E.R., Blackmond D.G., Buchwald S.L., (2003) Insights into the origin of high activity and stability of catalysts derived from bulky, electron-rich monophosphinobiaryl ligands in the Pd-catalyzed C-N bond formation. J Am Chem Soc; 125: 13978-13980. (Pubitemid 37420901)
30. Yin J., Buchwald S.L., (2002) Pd-catalyzed intermolecular amidation of aryl halides: the discovery that xantphos can be trans-chelating in a palladium complex. J Am Chem Soc; 124: 6043-6048. (Pubitemid 34552849)
31. Fukuyamaa T., Liu G., (1997) Stereocontrolled total synthesis of (±)-gelsemine. Pure Appl Chem; 69: 501-505.
32. Sumpter W.C., (1945) The chemistry of oxindole. Chem Rev; 37: 443-479.
33. Crestini C., Saladino R., (1994) A new efficient and mild synthesis of 2-oxindoles by one-pot Wolff-Kishner like reduction of isatin derivatives. Synth Commun; 24: 2835-2841. (Pubitemid 24329988)
34. Olgen S., Akaho E., Nebioglu D., (2005) Synthesis and anti-tyrosine kinase activity of 3-(substituted-benzylidene)-1, 3-dihydro-indolin derivatives: investigation of their role against p60c-Src receptor tyrosine kinase with the application of receptor docking studies. Farmaco; 60: 497-506. (Pubitemid 40943388)
35. Franzbalu G.S., Witzig S.R., McLaughlin C.J., Torres P., Madico G., Hernandez A., Degnan T.M., Cook B.M., Quenzer K.V., Ferguson M.R., Gilman H.R., (1998) Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J Clin Microbiol; 36: 362-366. (Pubitemid 28060296)
36. Hansen J., Bross P., (2010) A cellular viability assay to monitor drug toxicity. Methods Mol Biol; 648: 303-311.